Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,233 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chronic Obstructive Pulmonary Disease(COPD) Clear all

Conditions: COPD, Obstructive Lung Disease
Interventions: Lactobacillus GG, Sugar pill; Dietary Supplement · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: TD-4208, Placebo; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Bilevel positive airway pressure (BiPAP); Device
Lead sponsor: Philips Respironics; Industry
Eligibility: Up to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Not listed
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 54
States / cities: Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more

Conditions: COPD
Interventions: IN-DEX 1.0 mcg/kg, intranasal saline, IN-DEX 1.5 mcg/kg, intranasal saline, Placebo - Saline; Drug
Lead sponsor: Dayton VA Medical Center; Federal
Eligibility: 45 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Smoking, COPD
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 14
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 2,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 35
States / cities: Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tiotropium bromide inhalation solution, Placebo; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Emphysema, Pulmonary Disease, Chronic Obstructive
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 45 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Astegolimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 34
States / cities: Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 29 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: CSJ117, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Andalusia, Alabama • Crowley, Louisiana • New Orleans, Louisiana + 4 more

Conditions: Chronic Obstructive Pulmonary Disease, Emphysema
Interventions: Effectiveness of Lung Reduction Therapy; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Up to 75 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2256294; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler; Drug
Lead sponsor: William Stringer, md; Other
Eligibility: 40 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Torrance, California

Conditions: COPD, Cystic Fibrosis, Asthma, Healthy
Interventions: Hyperpolarized Helium-3; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: naloxone, normal saline; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: short chain fatty acid tracers; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: College Station, Texas

Conditions: COPD, Pulmonary Hypertension
Interventions: PRX-08066; Drug
Lead sponsor: Epix Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: COPD
Interventions: Ga-EC2115; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease, Arthritis, Pain
Interventions: Not listed
Lead sponsor: Angela N Fellner PhD CCRP; Other
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more

Search by objective public record fields.

Probiotic Use in Patients With Prior COPD Exacerbation

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)

AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients

NVA237 Versus Placebo 12-week Efficacy Study

Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

Integrative-omics of the Disordered COPD Small Airway Epithelium

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Biomarkers and Genetic Factors Related to Emphysema

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

Cost-Effectiveness of Lung Volume Reduction Surgery

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)

Short Chain Fatty Acid Metabolism in COPD

An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Imaging Activated Macrophages in the Lungs

Modifying Exercise for the COPD Patient

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)